Clinical relevance of lung-restricted antibodies in lung transplantation

Mahzad Akbarpour, Qiang Wu, Xianpeng Liu, Haiying Sun, Emilia Lecuona, Rade Tomic, Sangeeta Maruti Bhorade, Thalachallour Mohanakumar, Ankit Bharat*

*Corresponding author for this work

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Lung transplant is a definitive treatment for several end-stage lung diseases. However, the high incidence of allograft rejection limits the overall survival following lung transplantation. Traditionally, alloimmunity directed against human leukocyte antigens (HLA)has been implicated in transplant rejection. Recently, the clinical impact of non-HLA lung-restricted antibodies (LRA)has been recognized and extensive research has demonstrated that they may play a dominant role in the development of lung allograft rejection. The immunogenic lung-restricted antigens that have been identified include amongst others, collagen type I, collagen type V, and k-alpha 1 tubulin. Pre-existing antibodies against these lung-restricted antigens are prevalent in patients undergoing lung transplantation and have emerged as one of the predominant risk factors for primary graft dysfunction which limits short-term survival following lung transplantation. Additionally, LRA have been shown to predispose to chronic lung allograft rejection, the predominant cause of poor long-term survival. This review will discuss ongoing research into the mechanisms of development of LRA as well as the pathogenesis of associated lung allograft injury.

Original languageEnglish (US)
JournalHuman Immunology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Lung Transplantation
Lung
Antibodies
Allografts
HLA Antigens
Survival
Primary Graft Dysfunction
Collagen Type V
Antigens
Graft Rejection
Lung Injury
Tubulin
Collagen Type I
Research
Lung Diseases
Transplants
Incidence

Keywords

  • Antibodies
  • Lung transplant
  • Rejection

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

@article{a4d48d3f41c6483d826a5a599d9e68e3,
title = "Clinical relevance of lung-restricted antibodies in lung transplantation",
abstract = "Lung transplant is a definitive treatment for several end-stage lung diseases. However, the high incidence of allograft rejection limits the overall survival following lung transplantation. Traditionally, alloimmunity directed against human leukocyte antigens (HLA)has been implicated in transplant rejection. Recently, the clinical impact of non-HLA lung-restricted antibodies (LRA)has been recognized and extensive research has demonstrated that they may play a dominant role in the development of lung allograft rejection. The immunogenic lung-restricted antigens that have been identified include amongst others, collagen type I, collagen type V, and k-alpha 1 tubulin. Pre-existing antibodies against these lung-restricted antigens are prevalent in patients undergoing lung transplantation and have emerged as one of the predominant risk factors for primary graft dysfunction which limits short-term survival following lung transplantation. Additionally, LRA have been shown to predispose to chronic lung allograft rejection, the predominant cause of poor long-term survival. This review will discuss ongoing research into the mechanisms of development of LRA as well as the pathogenesis of associated lung allograft injury.",
keywords = "Antibodies, Lung transplant, Rejection",
author = "Mahzad Akbarpour and Qiang Wu and Xianpeng Liu and Haiying Sun and Emilia Lecuona and Rade Tomic and Bhorade, {Sangeeta Maruti} and Thalachallour Mohanakumar and Ankit Bharat",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.humimm.2019.04.016",
language = "English (US)",
journal = "Human Immunology",
issn = "0198-8859",
publisher = "Elsevier Inc.",

}

Clinical relevance of lung-restricted antibodies in lung transplantation. / Akbarpour, Mahzad; Wu, Qiang; Liu, Xianpeng; Sun, Haiying; Lecuona, Emilia; Tomic, Rade; Bhorade, Sangeeta Maruti; Mohanakumar, Thalachallour; Bharat, Ankit.

In: Human Immunology, 01.01.2019.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Clinical relevance of lung-restricted antibodies in lung transplantation

AU - Akbarpour, Mahzad

AU - Wu, Qiang

AU - Liu, Xianpeng

AU - Sun, Haiying

AU - Lecuona, Emilia

AU - Tomic, Rade

AU - Bhorade, Sangeeta Maruti

AU - Mohanakumar, Thalachallour

AU - Bharat, Ankit

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Lung transplant is a definitive treatment for several end-stage lung diseases. However, the high incidence of allograft rejection limits the overall survival following lung transplantation. Traditionally, alloimmunity directed against human leukocyte antigens (HLA)has been implicated in transplant rejection. Recently, the clinical impact of non-HLA lung-restricted antibodies (LRA)has been recognized and extensive research has demonstrated that they may play a dominant role in the development of lung allograft rejection. The immunogenic lung-restricted antigens that have been identified include amongst others, collagen type I, collagen type V, and k-alpha 1 tubulin. Pre-existing antibodies against these lung-restricted antigens are prevalent in patients undergoing lung transplantation and have emerged as one of the predominant risk factors for primary graft dysfunction which limits short-term survival following lung transplantation. Additionally, LRA have been shown to predispose to chronic lung allograft rejection, the predominant cause of poor long-term survival. This review will discuss ongoing research into the mechanisms of development of LRA as well as the pathogenesis of associated lung allograft injury.

AB - Lung transplant is a definitive treatment for several end-stage lung diseases. However, the high incidence of allograft rejection limits the overall survival following lung transplantation. Traditionally, alloimmunity directed against human leukocyte antigens (HLA)has been implicated in transplant rejection. Recently, the clinical impact of non-HLA lung-restricted antibodies (LRA)has been recognized and extensive research has demonstrated that they may play a dominant role in the development of lung allograft rejection. The immunogenic lung-restricted antigens that have been identified include amongst others, collagen type I, collagen type V, and k-alpha 1 tubulin. Pre-existing antibodies against these lung-restricted antigens are prevalent in patients undergoing lung transplantation and have emerged as one of the predominant risk factors for primary graft dysfunction which limits short-term survival following lung transplantation. Additionally, LRA have been shown to predispose to chronic lung allograft rejection, the predominant cause of poor long-term survival. This review will discuss ongoing research into the mechanisms of development of LRA as well as the pathogenesis of associated lung allograft injury.

KW - Antibodies

KW - Lung transplant

KW - Rejection

UR - http://www.scopus.com/inward/record.url?scp=85065166180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065166180&partnerID=8YFLogxK

U2 - 10.1016/j.humimm.2019.04.016

DO - 10.1016/j.humimm.2019.04.016

M3 - Review article

JO - Human Immunology

JF - Human Immunology

SN - 0198-8859

ER -